Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Fluoxetine has been the first antidepressive agent of the class of selective serotonine reuptake inhibitors (SSRI) to be introduced in therapy, back in 1987. The availability of SSRIs has meant a great advance in the treatment of major depression and other neuro-psychiatric pathologies. In this pape...

Full description

Bibliographic Details
Main Authors: Carlo Della Pepa, Mario Eandi
Format: Article
Language:English
Published: SEEd Medical Publishers 2003-09-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/775
id doaj-d9acc39306e84407b925719df22b4bc2
record_format Article
spelling doaj-d9acc39306e84407b925719df22b4bc22020-11-24T21:38:20ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2003-09-014312515210.7175/fe.v4i3.775720Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto genericoCarlo Della Pepa0Mario Eandi1Dipartimento di Farmacologia, Università di Torino
Dipartimento di Farmacologia, Università di Torino

Fluoxetine has been the first antidepressive agent of the class of selective serotonine reuptake inhibitors (SSRI) to be introduced in therapy, back in 1987. The availability of SSRIs has meant a great advance in the treatment of major depression and other neuro-psychiatric pathologies. In this paper we review the scientific and clinical research on fluoxetine that has been published in the last six years, as the prior work has been extensively examined in a review conducted on the tenth anniversary of its introduction on the market. The review focuses on cost minimization strategies that can be conducted following the introduction of low cost generic fluoxetine.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/775
collection DOAJ
language English
format Article
sources DOAJ
author Carlo Della Pepa
Mario Eandi
spellingShingle Carlo Della Pepa
Mario Eandi
Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
Farmeconomia: Health Economics and Therapeutic Pathways
author_facet Carlo Della Pepa
Mario Eandi
author_sort Carlo Della Pepa
title Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
title_short Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
title_full Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
title_fullStr Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
title_full_unstemmed Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
title_sort fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
publisher SEEd Medical Publishers
series Farmeconomia: Health Economics and Therapeutic Pathways
issn 2240-256X
publishDate 2003-09-01
description Fluoxetine has been the first antidepressive agent of the class of selective serotonine reuptake inhibitors (SSRI) to be introduced in therapy, back in 1987. The availability of SSRIs has meant a great advance in the treatment of major depression and other neuro-psychiatric pathologies. In this paper we review the scientific and clinical research on fluoxetine that has been published in the last six years, as the prior work has been extensively examined in a review conducted on the tenth anniversary of its introduction on the market. The review focuses on cost minimization strategies that can be conducted following the introduction of low cost generic fluoxetine.
url https://journals.seedmedicalpublishers.com/index.php/FE/article/view/775
work_keys_str_mv AT carlodellapepa fluoxetinaprofiloterapeuticoefarmacoeconomicodiunprodottogenerico
AT marioeandi fluoxetinaprofiloterapeuticoefarmacoeconomicodiunprodottogenerico
_version_ 1725934773179777024

Similar Items